Research
Metabolic changes associated with ageing impact immune responses against tumours

A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which ageing may promote lung cancer progression.
Moffitt Cancer Center researchers have found new insights into how metabolic changes associated with aging can impact immune responses against tumours.
Their study, published in Oncogene, explores how increased methylmalonic acid impairs the activation and effector functions of CD8+ T cells, immune cells that play a vital role in fighting cancer.
Methylmalonic acid levels are normally low in healthy individuals. Elevated levels have been linked to aging and vitamin B12 deficiency, raising questions about their role in cancer biology.
“Our research shows that methylmalonic acid not only increases with age but also makes CD8+ T cells weaker by disrupting their energy production,” said Ana Gomes, Ph.D., lead author on the study and principal investigator in the Molecular Oncology Department at Moffitt.
“This makes it harder for the immune system to fight cancer, suggesting that targeting methylmalonic acid could help improve cancer treatment.”
Researchers found that methylmalonic acid treatment significantly reduced the activity of CD8+ T cells, an important component of the immune response to tumours. The study’s results indicate that methylmalonic acid influences global gene expression in these cells, leading to the downregulation of key pathways involved in immune activation and metabolism.
The study also highlights the role of methylmalonic acid in skewing the tumour microenvironment, affecting not only T cells but also other immune cells, potentially contributing to a more favourable environment for tumour growth and metastasis.
These findings suggest that strategies aimed at reducing methylmalonic acid levels or counteracting its effects on CD8+ T cells could enhance antitumor immunity, particularly in older patients who are at greater risk for lung cancer.
News
Two teas or coffees a day could lower dementia risk, experts say
Research
Genetic influence on lifespan underestimated by half
News
Aerska raises US$39m for brain RNA medicines

Biotechnology company Aerska has raised US$39m in Series A funding to develop brain-delivered RNA medicines.
The company is developing treatments for neurological diseases, including genetically driven forms of Alzheimer’s disease.
This takes Aerska’s total funding to US$60m, months after its seed funding announcement in October 2025.
The company’s platform uses what it calls “brain shuttle” technology to help RNA therapeutics cross the blood-brain barrier, a protective membrane that normally prevents many drugs reaching the brain. RNA interference is a biological process where RNA molecules can silence or reduce the activity of specific genes.
The approach is designed to allow intravenous or subcutaneous administration, with the aim of achieving uniform brain distribution.
The financing was led by EQT Dementia Fund and age1, with participation from Iaso Ventures, alongside existing investors.
Chief executive and co-founder Jack O’Meara said: “The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration.
“Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically-driven forms of Alzheimer’s disease and other devastating brain disorders.”
As part of the financing, Arno de Wilde, managing director at EQT, Philip Scheltens, partner and head of the Dementia Fund at EQT, and Alex Colville, general partner at age1, will join Aerska’s board of directors.
Scheltens said: “For families facing diseases like Alzheimer’s, Aerska’s approach offers hope for preserving cognitive function and quality of life.
“The team’s strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches.
“We really look forward to working with this talented team to advance this groundbreaking platform.”
Technology4 weeks agoInterview: GlycanAge launch first hospital-based tests
News3 weeks agoShingles vaccine may slow biological ageing in older adults
News4 weeks agoOlder male athletes may face increased risk of serious heart problems during exercise
News3 weeks agoThousands of men in England to be offered life-extending prostate cancer drug
News3 weeks agoNanoparticles target disease proteins in dementia
News3 weeks agoL-Nutra raises US$36.5m in series D funding
News4 weeks agoBlood sugar spike after meals may increase Alzheimer’s risk
Insights4 weeks agoStudy reveals why memory declines with age





















